Moderna, Inc. Gain (Loss) on Sale of Leased Assets, Net, Operating Leases
Moderna, Inc. (MRNA) reported Gain (Loss) on Sale of Leased Assets, Net, Operating Leases of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-24.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnSaleOfLeasedAssetsNetOperatingLeases · last filed 2023-02-24
- Moderna, Inc. gain (loss) on sale of leased assets, net, operating leases for fiscal 2022 was $0.00.
- Moderna, Inc. gain (loss) on sale of leased assets, net, operating leases for fiscal 2021 was $0.00.
- Moderna, Inc. gain (loss) on sale of leased assets, net, operating leases for fiscal 2020 was -$62.00M.
- Moderna, Inc. gain (loss) on sale of leased assets, net, operating leases for fiscal 2019 was $0.00.
| Period end | Gain (Loss) on Sale of Leased Assets, Net, Operating Leases 12 month | Gain (Loss) on Sale of Leased Assets, Net, Operating Leases 12 month as first filed |
|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-24 | |
| 2021-12-31 | $0.00 10-K · filed 2023-02-24 | |
| 2020-12-31 | -$62.00M 10-K · filed 2023-02-24 | -$62.29M 10-K · filed 2021-02-26 |
| 2019-12-31 | $0.00 10-K · filed 2022-02-25 | |
| 2018-12-31 | $0.00 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |